Emerson Electric Co. (EMR)
Emerson Electric Co. NYSE
EMR at a glance
Emerson Electric Co. (EMR): Buy, 68/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($156.33 and $145.72).
- Earnings EMR beat estimates in 4 of its last 5 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $13.1M and made no open-market purchases over the last 18 months.
- Valuation P/E of 35.8 against 34.0 for the Industrials sector: broadly in line with peers (+5%).
As of October 15, 2026, Emerson Electric Co. (EMR) trades at $161.08. Wall Street's consensus target is $179.50 across 30 analysts. The 14-day RSI (daily closes) is 58, in neutral territory, and the price is above its 50-day simple moving average of $156.33.
Figures as of October 15, 2026.
Only on CleaRank
Figures we compute ourselves from EMR's own price, earnings and insider-filing history. Tap one to see it in context.
EMR Price Analysis
Market Metrics
Peer Benchmarking
Valuation vs Sector (Industrials)
Performance vs XLI
Sector Position Analysis
EMR Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
| Report | EPS estimate | EPS actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 4, 2026 | $1.68 | $1.71 | +1.79% | +2.29% | +3.49% |
| May 5, 2026 | $1.53 | $1.54 | +0.65% | +6.94% | -0.79% |
| Feb 3, 2026 | $1.41 | $1.46 | +3.55% | +3.43% | +6.31% |
| Nov 5, 2025 | $1.62 | $1.62 | +0.00% | -0.72% | -0.01% |
| Aug 6, 2025 | $1.51 | $1.52 | +0.66% | -0.82% | +0.80% |
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
As of October 15, 2026, EMR has beaten the analyst EPS estimate in 4 of its last 5 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on August 4, 2026, came in 1.79% above the estimate and the stock moved +2.29% in the first session.
EMR Analysis
- Given the neutral RSI, watch for a build-up of momentum above the 50-day SMA for potential entry points.
Emerson Electric Co. has a track record of meeting or exceeding EPS estimates, as seen in the Q3 2026 report where EPS surpassed expectations by 1.79%. This reliability supports continued investor confidence.
Source: Earnings ReportsThe majority of Wall Street analysts rate EMR as a 'Buy' or 'Strong Buy', with a median price target of $179.50, indicating an 11.4% potential upside. This consensus suggests a favorable view of the company's future performance.
Source: Wall Street AnalystsThe stock is trading above its 50-day SMA ($156.33) and 200-day SMA ($145.72), indicating a generally positive technical trend and potential for further upward movement.
Source: Technical AnalysisInsiders have sold a net of $13.1 million in stock, signaling a 'Moderate Sell Signal'. While not a strong bearish indicator, it suggests some caution among management regarding the stock's immediate prospects.
Source: Insider TransactionsEmerson Electric Co.'s P/E ratio of 35.78 is slightly higher than the sector median of 34, potentially making the stock vulnerable to corrections if growth falters or market sentiment shifts.
Source: Fundamental AnalysisKey Statistics
| Market Cap | 90.22B |
|---|---|
| P/E Ratio | 35.78 |
| EPS (TTM) | 4.57 |
| Dividend Yield | 1.38% |
| 52 Week High | 166.35 |
| 52 Week Low | 122.64 |
As of October 15, 2026, EMR trades at $161.08, with a market value of $90.22B, a P/E ratio of 35.78 and a dividend yield of 1.38%.
Earnings & Growth Analysis
Key Risks
Technical Indicators
| RSI (14-day) | 57.51 |
|---|---|
| MACD (12, 26) | 2.48 |
| SMA (50-day) | 156.33 |
| SMA (200-day) | 145.72 |
As of October 15, 2026, with EMR at $161.08, its 14-day RSI is 57.5 (neutral territory), its 50-day simple moving average is $156.33 and its 200-day is $145.72.
Calculated by CleaRank on daily closes as of October 15, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
As of October 15, 2026, EMR's 1-year correlation of daily returns is +0.70 with S&P 500 (SPY), +0.63 with Nasdaq 100 (QQQ), +0.28 with Bitcoin (BTC) and +0.21 with gold (XAU).
How does any other asset move with EMR? One year of daily closes, Pearson correlation.
EMR Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | JP Morgan | Maintains | Overweight |
| Sep 25, 2026 | TD Cowen | Maintains | Hold |
| Sep 25, 2026 | Wells Fargo | Initiates | Overweight |
| Aug 28, 2026 | Morgan Stanley | Maintains | Underweight |
| Aug 24, 2026 | DA Davidson | Maintains | Neutral |
| Aug 14, 2026 | Bernstein | Maintains | Outperform |
As of October 15, 2026, 30 Wall Street analysts cover EMR: 20 rate it a buy or strong buy, 8 a hold and 2 a sell or strong sell. Their 12-month price targets range from $104.00 to $205.00, with a median of $179.50, 11.4% above the price of $161.08.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
EMR Trade Plans
Specific entry, exit, and risk management levels
Long entry pick an entry style
Risk Management
Profit Targets (Based on Conservative Entry)
These levels come from EMR's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Growth of $10,000
A $10,000 investment in EMR in October 2016 would be worth about $32,417 today, compared with about $36,237 for the same investment in the S&P 500 benchmark. This is price change only; dividends paid along the way would add to it.
Compare with Another Ticker
EMR Drawdowns & Recovery
As of October 15, 2026, EMR's worst peak-to-trough fall over the last 10 years was -41.3% (September 2018 to March 2020); it regained that peak by December 2020, 9 months after the low, and 71% of 1-year holding periods ended with a gain.
From weekly closing values. A drawdown is the fall from the highest value reached so far to a later low.
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in EMR today could grow to about $22,721 by 2036 in the base case, with a 90th-percentile outcome near $74,864 and a 10th-percentile outcome around $6,896. The simulation models price only; at today's 1.38% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
EMR Stock Price Prediction: 2030
CleaRank's simulation projects a price near $224 for EMR by 2030 in the base case, from $161 today (1.4x over 4 years). The 10th-percentile path ends near $105. These are outcomes of a Monte Carlo simulation run on EMR's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile |
|---|---|---|---|
| 2027 | $120 | $175 | $255 |
| 2028 | $111 | $190 | $324 |
| 2029 | $107 | $206 | $396 |
| 2030 | $105 | $224 | $475 |
| 2031 | $104 | $243 | $564 |
Method: a lognormal simulation of EMR's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
People Also Watch
EMR Insider Trading Analysis
As of October 15, 2026, EMR insiders reported 10 open-market sales worth $13.1M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | KARSANBHAI SURENDRALAL LANCA
Chief Executive Officer
|
Sell | 9.7K | $1.6M |
| Aug 6, 2026 | TRAIN MICHAEL H
Officer
|
Sell | 7.3K | $1.2M |
| Aug 3, 2026 | NEWSTEAD JENNIFER
Director
|
Grant | 622 | - |
| Jun 1, 2026 | KRISHNAN RAM R,
Chief Operating Officer
|
Sell | 11.5K | $1.6M |
| Mar 10, 2026 | KARSANBHAI SURENDRALAL LANCA
Chief Executive Officer
|
Sell | 5.7K | $811.2K |
| Mar 9, 2026 | KRISHNAN RAM R,
Chief Operating Officer
|
Grant | 6.7K | - |
| Feb 10, 2026 | LEVATICH MATTHEW S
Director
|
Sell | 1.5K | $239.3K |
| Feb 9, 2026 | PIAZZA NICHOLAS J
Officer
|
Sell | 6.7K | $1.1M |
| Feb 5, 2026 | BLINN MARK A
Director
|
Sell | 2.9K | $438.9K |
| Feb 5, 2026 | KARSANBHAI SURENDRALAL LANCA
Chief Executive Officer
|
Grant | 5.6K | - |